BCS Wealth Management Makes New Investment in Thermo Fisher Scientific Inc. (NYSE:TMO)

BCS Wealth Management bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 419 shares of the medical research company’s stock, valued at approximately $218,000.

Other large investors have also added to or reduced their stakes in the company. WINTON GROUP Ltd bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $332,000. One Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 154.1% during the second quarter. One Capital Management LLC now owns 2,343 shares of the medical research company’s stock worth $1,296,000 after purchasing an additional 1,421 shares during the period. WealthPLAN Partners LLC lifted its holdings in Thermo Fisher Scientific by 6.5% during the 2nd quarter. WealthPLAN Partners LLC now owns 4,120 shares of the medical research company’s stock worth $2,279,000 after purchasing an additional 253 shares during the last quarter. Lmcg Investments LLC grew its holdings in Thermo Fisher Scientific by 2.9% in the 2nd quarter. Lmcg Investments LLC now owns 14,382 shares of the medical research company’s stock valued at $7,953,000 after buying an additional 400 shares in the last quarter. Finally, Moors & Cabot Inc. lifted its holdings in shares of Thermo Fisher Scientific by 1.7% during the second quarter. Moors & Cabot Inc. now owns 3,927 shares of the medical research company’s stock worth $2,172,000 after buying an additional 67 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of recent research reports. Barclays lowered their price target on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target for the company. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Trading Up 0.4 %

NYSE TMO opened at $557.49 on Wednesday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The business’s fifty day moving average is $529.85 and its 200 day moving average is $568.13. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market cap of $213.24 billion, a price-to-earnings ratio of 34.95, a price-to-earnings-growth ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. During the same period in the previous year, the business posted $5.69 earnings per share. The business’s quarterly revenue was up .2% compared to the same quarter last year. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Thermo Fisher Scientific declared that its board has authorized a stock buyback program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 47,150 shares of company stock valued at $25,954,465 in the last three months. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.